John Mascola, ModeX Therapeutics CSO
October 2, 2023 04:29 AM EDTUpdated 11:29 AM
Deals
Coronavirus

Ex-Warp Speed vac­cine leader nabs NextGen funds for Mod­eX Ther­a­peu­tics’ Covid-19 an­ti­bod­ies

Kyle LaHucik

Senior Reporter

A for­mer leader of Op­er­a­tion Warp Speed’s vac­cines ef­fort, which led to a quick roll­out of Covid jabs, is get­ting fed­er­al fund­ing for his biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times